Ponatinib, a third-generation TKI, targets the breakpoint cluster region (BCR) and Abelson (ABL) fusion protein, known as the oncoprotein BCR-ABL, in the management of Ph+ leukemia, including Ph+ B-cell acute lymphoblastic leukemia and chronic myeloid leukemia.1 Here, ABL1 is linked to B-cell acute lymphoblastic leukemia.